Zofran Linked to Abnormal Heart Rhythm

October 11, 2013

Important Information

Attorneys working with ClassAction.org are no longer reviewing claims for this case. The information here is for reference only. A list of open investigations can be viewed here.

Comments |

At A Glance

This Alert Affects:
Patients who took anti-nausea drug Zofran, used to prevent nausea and vomiting caused by chemotherapy, radiation and surgery.
Damages:
Research has indicated that Zofran may increase the risk of abnormal changes in the heart's electrical activity, which can lead to Torsade de Pointes, a potentially fatal heart rhythm.
Company(ies):
GlaxoSmithKline
Additional Details:
A QT interval is essentially the amount of time needed for the heart muscles to contract and recover.
Date:
The FDA released an initial safety announcement in Sept. 2011 about the potential link between Zofran and abnormal heart rhythms. The agency followed-up with a specific warning about the 32mg single intravenous dose of the drug and its potential to predispose patients to Torsade de Pointes.